Shanghai Institute of Organic Chemistry has described leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory disorders, Parkinson’s disease and Alzheimer’s disease, among others.